14
Sep 2020
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
01
Jul 2020
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
17
Sep 2019
BenevolentAI announces $90 million investment from Temasek
BenevolentAI has raised $90 million from Temasek. The funding will be used to scale and develop the Benevolent Platform as well as further progress BenevolentAI drug programmes developed in-house and through collaborations.
04
Sep 2019
BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform
BenevolentAI has collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients to more precisely target medicines.
